Corcept Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Corcept Therapeutics has a total shareholder equity of $638.8M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $784.3M and $145.4M respectively. Corcept Therapeutics's EBIT is $143.4M making its interest coverage ratio -6.2. It has cash and short-term investments of $380.3M.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | -6.2x |
| Cash | US$380.34m |
| Equity | US$638.84m |
| Total liabilities | US$145.42m |
| Total assets | US$784.26m |
Recent financial health updates
No updates
Recent updates
Corcept Therapeutics Incorporated (NASDAQ:CORT) Looks Just Right With A 25% Price Jump
Dec 04
Corcept Therapeutics Incorporated (NASDAQ:CORT) Stocks Shoot Up 28% But Its P/E Still Looks Reasonable
Sep 28If EPS Growth Is Important To You, Corcept Therapeutics (NASDAQ:CORT) Presents An Opportunity
Sep 06Investors Still Waiting For A Pull Back In Corcept Therapeutics Incorporated (NASDAQ:CORT)
Aug 01With Corcept Therapeutics Incorporated (NASDAQ:CORT) It Looks Like You'll Get What You Pay For
Apr 15We Like Corcept Therapeutics' (NASDAQ:CORT) Earnings For More Than Just Statutory Profit
Feb 22Corcept Therapeutics: Key Catalysts Ahead
Feb 19After Leaping 29% Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Are Not Flying Under The Radar
Dec 23Financial Position Analysis
Short Term Liabilities: CORT's short term assets ($467.0M) exceed its short term liabilities ($126.2M).
Long Term Liabilities: CORT's short term assets ($467.0M) exceed its long term liabilities ($19.2M).
Debt to Equity History and Analysis
Debt Level: CORT is debt free.
Reducing Debt: CORT had no debt 5 years ago.
Debt Coverage: CORT has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: CORT has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 02:03 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Corcept Therapeutics Incorporated is covered by 23 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| David Buck | B. Riley Securities, Inc. |
| Edward Nash | Canaccord Genuity |